Hong Kong: Researchers in Japan have designed a test to identify patients who are likely to be resistant to imatinib, the standard drug for treating leukemia or cancer of the blood cells. Such a test is important as imatinib resistance occurs usually to relapse patients, who tend to deteriorate very rapidly if they are given the wrong treatment.
New drugs being developed for treating CML claim to overcome imatinib resistance, but until now, it is difficult to tell who has that resistance. Using this test developed by Ohba and his colleagues, blood samples are collected from patients and then cultured and tested to see if they are resistant to imatinib. These tests should help doctors determine if the patient may require stronger doses, combination therapy, or other drugs, Ohba said. Bureau Report
Pune blast: ATS tracking online chats of IM terrorists
Devotees throng Mathura on the occassion of Guru Purnima
Shirdi Sai Baba is not God or Guru, says Shankaracharya
UPSC aspirants protest outside Rajnath Singh`s residence